Compass Therapeutics
Update in progressCMPX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company focused on antibody-based therapies. Its lead candidate, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A to disrupt tumor blood vessel formation. The pipeline also includes CTX-471, an IgG4 antibody that agonizes CD137; CTX-8371, a PD-1/PD-L1 bispecific inhibitor; and CTX-10726, a PD-1/VEGF-A bispecific. Founded in 2014 and based in Boston.
Company score
- Sentiment
- 0.25
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.41
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Thomas J. Schuetz M.D., Ph.D.
- Founded2014
- Employees39
- Websitewww.compasstherapeutics.com
Identifiers
- ISINUS20454B1044
- FIGIBBG00LPXKF25
- CUSIP20454B104
- CIK0001738021